PT - JOURNAL ARTICLE AU - Safari, Abdollah AU - Helisaz, Hamed AU - Salmasi, Shahrzad AU - Adelakun, Adenike AU - De Vera, Mary A. AU - Andrade, Jason G. AU - Deyell, Marc W. AU - Loewen, Peter TI - Association between oral anticoagulant adherence and serious clinical outcomes in patients with atrial fibrillation: A long-term retrospective cohort study AID - 10.1101/2023.07.18.23292847 DP - 2024 Jan 01 TA - medRxiv PG - 2023.07.18.23292847 4099 - http://medrxiv.org/content/early/2024/03/21/2023.07.18.23292847.short 4100 - http://medrxiv.org/content/early/2024/03/21/2023.07.18.23292847.full AB - Background Patients with atrial fibrillation (AF) are frequently nonadherent to oral anticoagulants (OACs) prescribed for stroke and systemic embolism (SSE) prevention. We quantified the relationship between OAC adherence and AF clinical outcomes using methods not previously applied to this problem.Methods Retrospective observational cohort study of incident cases of AF from population-based administrative data over 23 years. The exposure of interest was proportion of days covered (PDC) during 90 days before an event or end of follow-up. Cox proportional hazard models were used to evaluate time to first SSE and the composite of SSE, TIA, or death, and several secondary outcomes.Results 44,172 patients were included with median follow-up of 6.7 years. For DOACs, each 10% decrease in adherence was associated with a 14% increased hazard of SSE and 5% increased hazard of SSE, TIA, or death. For VKA the corresponding increase in SSE hazard was 3%. Receiving DOAC or VKA was associated with primary outcome hazard reduction across most the PDC spectrum. Differences between VKA and DOAC were statistically significant for all efficacy outcomes and at most adherence levels.Conclusions Even small reductions in OAC adherence in patients with AF were associated with significant increases in risk of stroke, with greater magnitudes for DOAC than VKA. DOAC recipients may be more vulnerable than VKA recipients to increased risk of stroke and death even with small reductions in adherence. The worsening efficacy outcomes associated with decreasing adherence occurred without the benefit of major bleeding reduction.Competing Interest StatementDr. Andrade has received honoraria from Bayer, Biosense-Webster, BMS Pfizer, Medtronic, and Servier, as well as Grants from Medtronic. Dr. Deyell has received honoraria from Pfizer, Servier, and Bayer. Other authors have no conflicts of interest to disclose.Funding StatementThis research was supported by Canadian Institutes of Health Research grant (FRN 168896). Dr. Loewens research is also partially supported by the UBC David H MacDonald Professorship in Clinical Pharmacy (Vancouver, Canada). Dr. Salmasis research was supported by a Canadian Institutes of Health Research Postdoctoral Fellowship award.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Clinical Research Ethics Board of the University of British Columbia gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAccess to data provided by the Data Stewards is subject to approval but can be requested for research projects through the Data Stewards or their designated service providers. The following data sets were used in this study: Medical Services Plan (MSP), Discharge Abstract Database (DAD), Consolidation File, Vital Statistics Database, and PharmaNet. You can find further information regarding these data sets by visiting the PopData project webpage at: https://my.popdata.bc.ca/project_listings/17-149/collection_approval_dates. All inferences, opinions, and conclusions drawn in this publication are those of the author(s), and do not reflect the opinions or policies of the Data Steward(s).